[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![ClearPath100 Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1896831415054221312.png) ClearPath [@ClearPath100](/creator/twitter/ClearPath100) on x XXX followers
Created: 2025-07-23 18:18:37 UTC

$XBI $QURE may be next after $ABVX.

-AMT-130 (HD). Best-case rev.: $1.5–3 bln/year. Based on one-time treatment pricing and 5–10% patient uptake.

-AMT-261 (TLE) targeting drug-resistant focal epilepsy. Best-case: $2–4 bln/year.

Combined peak potential for uniQure is $4–7 bln.


XXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1948085356185760054/c:line.svg)

**Related Topics**
[focal](/topic/focal)
[rev](/topic/rev)
[$abvx](/topic/$abvx)
[$qure](/topic/$qure)
[$xbi](/topic/$xbi)

[Post Link](https://x.com/ClearPath100/status/1948085356185760054)